Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

References

• Brincker H, Pedersen NT, Bendix-Hansen K, Johansen P. Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinico-pathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma 2000;39:531–541.
   PubMed Web of Science ®Google Scholar
• Muller A, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. Ann Haematol 1999;84:1–12.
   Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997;8:973–978.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival–a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945–2953.
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838–1844.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342–1349.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Fyfe MAE, Lewis J. Long term remission durabilityand functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984;2:898–902.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Cavallin-Stahl E, CHOP versus MACOP-B in aggressive lymphoma – a Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10:1079–1086.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984;32:269–273.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530–2539.
   PubMed Web of Science ®Google Scholar
• Meyer R, Browman G, Samosh M, Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2386–2393.
   PubMed Web of Science ®Google Scholar
• Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33:2–7.
   PubMed Web of Science ®Google Scholar
• Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 2006;33(Suppl. 8):S22–S27.
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman HE, Lipshults SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777–3784.
   PubMed Web of Science ®Google Scholar
• Visani G, Isidori A. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther 2009;9:357–363.
   PubMed Web of Science ®Google Scholar
• Ostro MJ. Liposomes: from the bench to the marketplace – doxorubicin as an example. Liposomes in the therapy of infectious diseases and cancerIn: Fidler IJ, Lopez-Berestein G, editors. Alan LissNew York1989. pp 155–163.
   Google Scholar
• Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990;53:183–190.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Michiels EMC, Caron HN, Kremer LCM. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;(5): CD005006.
   Google Scholar
• Batist G, Ramakriskan G, Rao CS, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444–1454.
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25–36.
   PubMed Web of Science ®Google Scholar
• Anderlini P, Benjamin RS, Wong FC, Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995;13:2827–2834.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, WHO classification of tumours of haematopoietic and lymphoid tissues. LyonIARC Press2008.
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Levine AM, Tulpule A, Espina B, Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662–2670.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Tulpule A, Espina BM, Berman N, Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006;7:59–64.
   PubMedGoogle Scholar
• Rigacci L, Mappa S, Nassi L, Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007;25:198–203.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• O'Brien MER, Wigler N, Inbar M, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–449.
   PubMed Web of Science ®Google Scholar
• Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31:5–15.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Bolcsak LE, Batist G, Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14:239–246.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ewer MS, Martin FJ, Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31:161–181.
   PubMed Web of Science ®Google Scholar
• Limat S, Demesmay K, Voillat L, Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277–281.
   PubMed Web of Science ®Google Scholar